India-based pharmaceutical company Eris Lifesciences is set to acquire Biocon Biologics’s nephrology and dermatology formulations unit for a consideration of Rs 366 crore, inclusive of working capital conveyed as part of the deal, according to a company statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
